MSK Sacituzumab Govitecan Phase 2 Trial (NCT06477419)

Memorial Sloan Kettering Phase 2 trial of sacituzumab govitecan for previously treated diffuse pleural mesothelioma (NCT06477419) is recruiting.

By James Thornton 2 min read
Published: Updated:
Medically Reviewed
MSK Sacituzumab Govitecan Phase 2 Trial (NCT06477419)

Memorial Sloan Kettering Cancer Center is recruiting people with previously treated diffuse pleural mesothelioma for a Phase 2 clinical trial of sacituzumab govitecan, an antibody-drug conjugate targeting TROP-2.

The trial, designated NCT06477419, is enrolling at MSK sites across New York and New Jersey. Collaborators include the U.S. Department of Defense and Gilead Sciences.

About the Study

Participants receive sacituzumab govitecan-hziy until disease progression, intolerable side effects, or a decision by the participant or study doctor to stop treatment. Eligibility requires pathologically confirmed diffuse pleural mesothelioma, at least one prior systemic therapy (such as platinum and pemetrexed, immunotherapy, or a combination), measurable disease, and adequate organ function. The primary endpoint is overall response rate.

Treatment Approach

This trial does not test checkpoint inhibitor immunotherapy. Sacituzumab govitecan is an antibody-drug conjugate that targets TROP-2 on tumor cells and delivers a topoisomerase I inhibitor payload (SN-38).

Key trial details:

  • Phase: Phase 2
  • Sponsor: Memorial Sloan Kettering Cancer Center
  • Intervention: Sacituzumab govitecan-hziy
  • Status: Recruiting

Why This Trial Matters

Sacituzumab govitecan is already approved in other tumor types. Testing it in mesothelioma evaluates a different mechanism of action for people whose disease has progressed on standard chemotherapy and checkpoint inhibitors.

Memorial Sloan Kettering is one of the leading mesothelioma treatment centers in the United States.

Study Locations

The trial is recruiting at Memorial Sloan Kettering Cancer Center sites, including:

  • MSK Main Campus, New York
  • MSK Westchester, New York
  • MSK Commack, New York
  • MSK Basking Ridge, New Jersey
  • MSK Monmouth, New Jersey
  • MSK Bergen (Montvale), New Jersey

Refer to ClinicalTrials.gov for the full, current list of participating sites.

How to Enroll

Patients interested in this trial should:

  1. Discuss eligibility with their oncologist
  2. Review the full eligibility criteria on ClinicalTrials.gov
  3. Contact the study coordinator for screening